Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 41CNS 35Gastrointestinal 32Breast 29Lymphoid 14Head & Neck 12Gynecologic 10Thoracic 8Other hematologic neoplasm 7Sarcoma 6Tumor-Agnostic 5Other solid neoplasm 5Plasma cell 2Myeloid 2Endocrine 2Dermatologic 2

Conditions

Carcinoma, Neuroendocrine 2

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Magnetic Resonance Imaging × Endocrine × Clear all
NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The First Affiliated Hospital of Xiamen University

Phase NA Recruiting
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01879657 2025-08-06

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Radio Isotope Therapy of America

Phase NA Completed
169 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡